Poor, pregnant with third child? Even the state’s giving up on you. Why Less For More     * The ministry of health and family welfare wants to target poor, pregnant women with more than two children, take away entitlements and benefits     * Critics say the two-child norm will severely restrict the number of beneficiaries of the Janani Suraksha Yojana scheme. The scheme, launched in 2005, has been a great success.     *...

While ‘data exclusivity’ clauses will not feature in the India-European Union free trade agreement (FTA), the threat posed by the impending deal to the world’s supply of cheap generic drugs is far from over. India’s commerce and industry minister Anand Sharma assured Michel Sidibe, chief of the United Nations joint programme on HIV and AIDS (UNAIDS) at a meeting this week that India would reject attempts by pharmaceutical giants to include...

An unholy nexus between various healthcare providers, including doctors and private hospitals, has become a stumbling block in delivering benefits to the people at a time when Dispur is pumping in huge funds to bring improvement in the health sector. This was revealed in a multiple-stage survey conducted by Consumer Unity & Trust Society International, a reputed NGO. The survey has found that the government’s various welfare schemes like providing free medicines...

  Can we agree in this country on a floor of human dignity below which we will not allow any human being to fall? No child, woman or man in this land will sleep hungry. No person shall be forced to sleep under the open sky. No parent shall send their child out to work instead of to school. And no one shall die because they cannot afford the cost of...

India’s FTAs pip generic drugs production Lot More For Less     * Generic drugs from India play a major role as antiretroviral drugs across the developing world     * A 2010 study says 80% of the medicines used by donor-funded programmes to treat people with HIV were sourced from India     * It’s cut down treatment costs drastically, from $10,000 to $80     * Stronger IP regimes may hamper production of generics *** The right of...